Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Research on the epigenetic modification of pancreatic cancer vaccine.

Cao W, Zhou G, Qiu J, Xu L, Ding X, Zhang H, Zhou X.

Hepatogastroenterology. 2014 Mar-Apr;61(130):272-7.

PMID:
24901123
2.

Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice.

Tao Y, Lin F, Li T, Xie J, Shen C, Zhu Z.

Oncol Res. 2013;21(6):307-16. doi: 10.3727/096504014X13983417587320.

PMID:
25198660
3.

Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.

Lee YS, Kim SH, Cho JA, Kim CW.

Exp Mol Med. 2011 May 31;43(5):281-90. doi: 10.3858/emm.2011.43.5.029.

4.

Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes.

Otten LA, Tacchini-Cottier F, Lohoff M, Annunziato F, Cosmi L, Scarpellino L, Louis J, Steimle V, Reith W, Acha-Orbea H.

J Immunol. 2003 Feb 1;170(3):1150-7.

5.

Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.

Patel DR, Li W, Park JS, Sofi MH, Gourley TS, Hangoc G, Kaplan MH, Chang CH.

Cell Immunol. 2005 Jan;233(1):30-40.

PMID:
15876426
6.

Altered Th1 cell differentiation programming by CIITA deficiency.

Patel DR, Kaplan MH, Chang CH.

J Immunol. 2004 Nov 1;173(9):5501-8.

7.
8.
10.

EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion.

Ziegler A, Heidenreich R, Braumüller H, Wolburg H, Weidemann S, Mocikat R, Röcken M.

Blood. 2009 Apr 9;113(15):3494-502. doi: 10.1182/blood-2008-08-175109. Epub 2009 Feb 2.

11.
12.
13.
14.

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Knutson KL, Disis ML.

Cancer Immunol Immunother. 2005 Aug;54(8):721-8. Epub 2005 Jan 27. Review.

PMID:
16010587
15.

Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.

Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y.

Oncol Rep. 2009 Aug;22(2):337-43.

PMID:
19578774
16.

Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.

Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A.

J Immunother. 2005 Jul-Aug;28(4):332-42.

PMID:
16000951
17.
18.

MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.

Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ.

Glycoconj J. 2001 Nov-Dec;18(11-12):931-42.

PMID:
12820727
19.

Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.

Holtz R, Choi JC, Petroff MG, Piskurich JF, Murphy SP.

Biol Reprod. 2003 Sep;69(3):915-24. Epub 2003 May 14.

20.

Epigenetic targeting in pancreatic cancer.

van Kampen JG, Marijnissen-van Zanten MA, Simmer F, van der Graaf WT, Ligtenberg MJ, Nagtegaal ID.

Cancer Treat Rev. 2014 Jun;40(5):656-64. doi: 10.1016/j.ctrv.2013.12.002. Epub 2014 Jan 3. Review.

PMID:
24433955
Items per page

Supplemental Content

Write to the Help Desk